Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following topics do you feel will be most relevant to your practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What emerging trends in biomarker testing are you most excited about?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following trials is most likely to be most practice changing?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following treatments is most likely to change your clinical practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important area for research in late-stage EGFR-mutant NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following topics do you feel will be most relevant to your practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What emerging trends in biomarker testing are you most excited about?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following trials is most likely to be most practice changing?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following treatments is most likely to change your clinical practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important area for research in late-stage EGFR-mutant NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following topics do you feel will be most relevant to your practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What emerging trends in biomarker testing are you most excited about?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following trials is most likely to be most practice changing?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following treatments is most likely to change your clinical practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important area for research in late-stage EGFR-mutant NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following topics do you feel will be most relevant to your practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What emerging trends in biomarker testing are you most excited about?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following trials is most likely to be most practice changing?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following treatments is most likely to change your clinical practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important area for research in late-stage EGFR-mutant NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following topics do you feel will be most relevant to your practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What emerging trends in biomarker testing are you most excited about?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following trials is most likely to be most practice changing?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following treatments is most likely to change your clinical practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important area for research in late-stage EGFR-mutant NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following topics do you feel will be most relevant to your practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What emerging trends in biomarker testing are you most excited about?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following trials is most likely to be most practice changing?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following treatments is most likely to change your clinical practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important area for research in late-stage EGFR-mutant NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following topics do you feel will be most relevant to your practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What emerging trends in biomarker testing are you most excited about?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following trials is most likely to be most practice changing?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following treatments is most likely to change your clinical practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important area for research in late-stage EGFR-mutant NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following topics do you feel will be most relevant to your practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What emerging trends in biomarker testing are you most excited about?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following trials is most likely to be most practice changing?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following treatments is most likely to change your clinical practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important area for research in late-stage EGFR-mutant NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following topics do you feel will be most relevant to your practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What emerging trends in biomarker testing are you most excited about?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following trials is most likely to be most practice changing?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which of the following treatments is most likely to change your clinical practice?
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Poll
Which is the most important area for research in late-stage EGFR-mutant NSCLC?
touchCLINICAL PERSPECTIVES
A modular programme that includes a variety of interviews with experts and a patient, as well as downloadable resources. Close
A modular programme that includes a variety of interviews with experts and a patient, as well as downloadable resources. Close
- Share this Activity
- CE/CME Accredited
Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease
Claim Credit-
PART 1 of 9 Skip to Modules
- Time: 08:53
Module 1 - Part 1: EGFR-mutant NSCLC: Navigating the horizon in EGFR-mutant NSCLC
Dr Helena Yu, course director and thoracic oncologist, discusses the unmet needs of patients with EGFR-mutant metastatic non-small cell lung cancer (NSCLC) by highlighting the current challenges, areas for further research and clinical trial landscape.
After watching this activity, participants should be better able to:
- Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, including lung cancer specialists, pulmonologists, pathologists and oncology nurses involved in the management of patients with NSCLC.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
Dr Antonio Passaro discloses: Consultancy fees from Bayer and Johnson & Johnson (Janssen Pharmaceuticals). Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GSK, Johnson & Johnson (Janssen Pharmaceuticals), Merck Sharp and Dohme, MundiPharma, Novartis, Pfizer and Roche.
Content Reviewer
Danielle Walker, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Rebecca Franklin discloses: Independent contractor relationships with Fishawack Communications (relationship terminated).
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring Module 1 activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.5 Category 1 credits for completing this module. NCCPA accepts AMA PRA Category 1 CreditTMÂ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMÂ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 0.5 contact hours may be earned by learners who successfully complete this continuing nursing education module. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE module.
This module is awarded 0.5 ANCC pharmacotherapeutic contact hours.
Date of original release: 26 September 2024. Date credits expire: 26 September 2025.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
EBAC® Accreditation
touchIME is an EBAC® accredited provider since 2023.
This module is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.5 hours of effective education time.
The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.
Requirements for Successful Completion
Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.
Time to complete Module 1: 0.5 hours
If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org
-
PART 2 of 9 Skip to Modules
- Time: 09:37
Module 1 - Part 2: EGFR-mutant NSCLC: Evaluating the latest advances in therapeutic strategies
Dr Antonio Passaro, an oncologist specializing in lung cancer, provides insights into the latest advances in therapeutic strategies for EGFR-mutant metastatic non-small cell lung cancer (NSCLC), focusing on recent clinical trial data in both the first- and second-line settings.
After watching this activity, participants should be better able to:
- Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, including lung cancer specialists, pulmonologists, pathologists and oncology nurses involved in the management of patients with NSCLC.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
Dr Antonio Passaro discloses: Consultancy fees from Bayer and Johnson & Johnson (Janssen Pharmaceuticals). Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GSK, Johnson & Johnson (Janssen Pharmaceuticals), Merck Sharp and Dohme, MundiPharma, Novartis, Pfizer and Roche.
Content Reviewer
Danielle Walker, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Rebecca Franklin discloses: Independent contractor relationships with Fishawack Communications (relationship terminated).
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring Module 1 activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.5 Category 1 credits for completing this module. NCCPA accepts AMA PRA Category 1 CreditTMÂ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMÂ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 0.5 contact hours may be earned by learners who successfully complete this continuing nursing education module. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE module.
This module is awarded 0.5 ANCC pharmacotherapeutic contact hours.
Date of original release: 26 September 2024. Date credits expire: 26 September 2025.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
EBAC® Accreditation
touchIME is an EBAC® accredited provider since 2023.
This module is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.5 hours of effective education time.
The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.
Requirements for Successful Completion
Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.
Time to Complete Module 1: 0.5 hours
If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org
-
PART 3 of 9 Skip to Modules
- Time: 13:22
Module 1 - Part 3: EGFR-mutant NSCLC: Practical insights and implications for NSCLC practice
Dr Helena Yu provides an overview of the current treatment options for EGFR-mutant metastatic non-small cell lung cancer (NSCLC). She uses a patient case to explore both the existing therapies available at diagnosis and at the point of disease progression, as well as how ongoing research and the advent of new therapies and combination strategies might impact future treatment approaches.
After watching this activity, participants should be better able to:
- Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.
- Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, including lung cancer specialists, pulmonologists, pathologists and oncology nurses involved in the management of patients with NSCLC.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
Dr Antonio Passaro discloses: Consultancy fees from Bayer and Johnson & Johnson (Janssen Pharmaceuticals). Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GSK, Johnson & Johnson (Janssen Pharmaceuticals), Merck Sharp and Dohme, MundiPharma, Novartis, Pfizer and Roche.
Content Reviewer
Danielle Walker, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Rebecca Franklin discloses: Independent contractor relationships with Fishawack Communications (relationship terminated).
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring Module 1 activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.5 Category 1 credits for completing this module. NCCPA accepts AMA PRA Category 1 CreditTMÂ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMÂ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 0.5 contact hours may be earned by learners who successfully complete this continuing nursing education module. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE module.
This module is awarded 0.5 ANCC pharmacotherapeutic contact hours.
Date of original release: 26 September 2024. Date credits expire: 26 September 2025.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
EBAC® Accreditation
touchIME is an EBAC® accredited provider since 2023.
This module is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.5 hours of effective education time.
The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.
Requirements for Successful Completion
Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.
Time to Complete Module 1: 0.5 hours
If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org
-
PART 4 of 9 Skip to Modules
- Time: 07:55
Module 2 – Part 1: Advances in the treatment landscape for EGFR-wildtype NSCLC
Dr Helena Yu, course director and thoracic oncologist, discusses the unmet needs of patients with EGFR-wildtype metastatic non-small cell lung cancer (NSCLC) by highlighting the current challenges, areas for further research and clinical trial landscape.
After watching this activity, participants should be better able to:
- Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, including lung cancer specialists, pulmonologists, pathologists and oncology nurses involved in the management of patients with NSCLC.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
Dr Aaron Lisberg discloses: Advisory board or panel speaker fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron and Sanofi group of companies. Consultancy fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron and Sanofi group of companies. Grants/research support from AstraZeneca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics and WindMIL Therapeutics, Inc.
Dr Sara Pilotto discloses: Advisory board/panel speaker fees from Amgen, AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi and Takeda. Consultancy fees from Boehringer Ingelheim. Speaker’s bureau fees from Amgen, AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi and Takeda.
Content Reviewer
Danielle Walker, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Rebecca Franklin discloses: Independent contractor relationships with Fishawack Communications (relationship terminated).
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring activity (Modules 1 and 2) for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advanced Practice Providers
Physician Assistants may claim a maximum of 1.0 Category 1 credits for completing Module 1 and 2. NCCPA accepts AMA PRA Category 1 CreditTMÂ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMÂ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.0 contact hours may be earned by learners who successfully complete these continuing nursing education modules. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE module.
Modules 1 and 2 are awarded 1.0 ANCC pharmacotherapeutic contact hours.
Date of original release (Module 2): 31 October 2024. Date credits expire: 31 October 2025.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
EBAC® Accreditation
touchIME is an EBAC® accredited provider since 2023.
This module is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1.0 hour of effective education time.
The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.
Requirements for Successful Completion
Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.
Time to complete Module 1 and 2: 1.0 hour
If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org
-
PART 5 of 9 Skip to Modules
- Time: 15:26
Module 2 – Part 2: EGFR-wildtype NSCLC: Insights from the latest data and strategies for improvement
Dr Aaron Lisberg, a thoracic oncologist specializing in patients with advanced malignancies, with a focus on lung cancer, provides insights into the latest advances in therapeutic strategies for EGFR-wildtype metastatic non-small cell lung cancer (NSCLC), focusing on recent clinical trial data in both the first- and second-line settings
After watching this activity, participants should be better able to:
- Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, including lung cancer specialists, pulmonologists, pathologists and oncology nurses involved in the management of patients with NSCLC.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
Dr Aaron Lisberg discloses: Advisory board or panel speaker fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron and Sanofi group of companies. Consultancy fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron and Sanofi group of companies. Grants/research support from AstraZeneca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics and WindMIL Therapeutics, Inc.
Dr Sara Pilotto discloses: Advisory board/panel speaker fees from Amgen, AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi and Takeda. Consultancy fees from Boehringer Ingelheim. Speaker’s bureau fees from Amgen, AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi and Takeda.
Content Reviewer
Danielle Walker, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Rebecca Franklin discloses: Independent contractor relationships with Fishawack Communications (relationship terminated).
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring activity (Modules 1 and 2) for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advanced Practice Providers
Physician Assistants may claim a maximum of 1.0 Category 1 credits for completing Module 1 and 2. NCCPA accepts AMA PRA Category 1 CreditTMÂ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMÂ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.0 contact hours may be earned by learners who successfully complete these continuing nursing education modules. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE module.
Modules 1 and 2 are awarded 1.0 ANCC pharmacotherapeutic contact hours.
Date of original release (Module 2): 31 October 2024. Date credits expire: 31 October 2025.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
EBAC® Accreditation
touchIME is an EBAC® accredited provider since 2023.
This module is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1.0 hour of effective education time.
The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.
Requirements for Successful Completion
Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.
Time to complete Module 1 and 2: 1.0 hour
If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org
-
PART 6 of 9 Skip to Modules
- Time: 09:03
Module 2 – Part 3: EGFR-wildtype NSCLC: Practical insights and implications for NSCLC practice
Dr Sara Pilotto, a medical oncologist specializing in thoracic malignancies, provides an overview of the current treatment options for EGFR-wildtype metastatic non-small cell lung cancer (NSCLC). She uses a patient case to explore both the existing therapies available at diagnosis and key considerations at disease progression, as well as how ongoing research and the advent of new therapies, such as antibody–drug conjugates, might impact future treatment approaches.
After watching this activity, participants should be better able to:
- Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing
- Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, including lung cancer specialists, pulmonologists, pathologists and oncology nurses involved in the management of patients with NSCLC.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
Dr Aaron Lisberg discloses: Advisory board or panel speaker fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron and Sanofi group of companies. Consultancy fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron and Sanofi group of companies. Grants/research support from AstraZeneca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics and WindMIL Therapeutics, Inc.
Dr Sara Pilotto discloses: Advisory board/panel speaker fees from Amgen, AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi and Takeda. Consultancy fees from Boehringer Ingelheim. Speaker’s bureau fees from Amgen, AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi and Takeda.
Content Reviewer
Danielle Walker, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Rebecca Franklin discloses: Independent contractor relationships with Fishawack Communications (relationship terminated).
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring activity (Modules 1 and 2) for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advanced Practice Providers
Physician Assistants may claim a maximum of 1.0 Category 1 credits for completing Module 1 and 2. NCCPA accepts AMA PRA Category 1 CreditTMÂ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMÂ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.0 contact hours may be earned by learners who successfully complete these continuing nursing education modules. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE module.
Modules 1 and 2 are awarded 1.0 ANCC pharmacotherapeutic contact hours.
Date of original release (Module 2): 31 October 2024. Date credits expire: 31 October 2025.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
EBAC® Accreditation
touchIME is an EBAC® accredited provider since 2023.
This module is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1.0 hour of effective education time.
The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.
Requirements for Successful Completion
Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.
Time to complete Module 1 and 2: 1.0 hour
If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org
-
PART 7 of 9 Skip to Modules
- Time: 09:44
Module 3 - Part 1: Novel strategies, care pathways and side-effect management
Jackie Fenemore, a lung cancer nurse clinician, looks at how understanding the latest therapies can significantly impact patient care by effectively managing side effects and aligning treatment plans with patient expectations. She also highlights the essential supports that can be implemented to guide patients through the complexities of lung cancer care pathways.
After watching this activity, participants should be better able to:
- Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, including lung cancer specialists, pulmonologists, pathologists and oncology nurses involved in the management of patients with NSCLC.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
Ms Jackie Fenemore discloses: Advisory board/panel fees from Roche (relationship terminated).
Prof. Egbert Smit discloses: Advisory board or panel fees from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen Pharmaceuticals, Merck Serono, MSD, Pfizer and Takeda. Consultancy fees from Eli Lilly. Grants/research support from AstraZeneca, BMS and Merck.
Content Reviewer
Danielle Walker, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Rebecca Franklin discloses: Independent contractor relationships with Fishawack Communications (relationship terminated).
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring activity (Modules 1, 2 and 3) for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advanced Practice Providers
Physician Assistants may claim a maximum of 1.5 Category 1 credits for completing Modules 1, 2 and 3. NCCPA accepts AMA PRA Category 1 CreditTMÂ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMÂ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.5 contact hours may be earned by learners who successfully complete these continuing nursing education modules. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE module.
Modules 1, 2 and 3 are awarded 1.5 ANCC pharmacotherapeutic contact hours.
Date of original release (Module 3): 28 November 2024. Date credits expire: 28 November 2025.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
EBAC® Accreditation
touchIME is an EBAC® accredited provider since 2023.
This module is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1.5 hours of effective education time.
The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.
Requirements for Successful Completion
Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.
Time to complete Modules 1, 2 and 3: 1.5 hours
If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org
-
PART 8 of 9 Skip to Modules
- Time: 11:14
Module 3 - Part 2: Implications of novel treatments on the shifting biomarker landscape
Prof. Dr Egbert Smit, a professor of pulmonary medicine, emphasizes the important role of biomarker testing in patients with EGFR-mutant and wildtype non-small cell lung cancer (NSCLC). He discusses how advances in the treatment landscape are influencing biomarker testing strategies and how this impacts patient care, as well as the challenges clinicians face, including sample acquisition, the need for timely testing, interpretation of results, and integration of findings into personalized treatment approaches.
After watching this activity, participants should be better able to:
- Describe the evolving landscape for biomarker testing in NSCLC and how this may impact current and future treatment decision making
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, including lung cancer specialists, pulmonologists, pathologists and oncology nurses involved in the management of patients with NSCLC.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
Ms Jackie Fenemore discloses: Advisory board/panel fees from Roche (relationship terminated).
Prof. Egbert Smit discloses: Advisory board or panel fees from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen Pharmaceuticals, Merck Serono, MSD, Pfizer and Takeda. Consultancy fees from Eli Lilly. Grants/research support from AstraZeneca, BMS and Merck.
Content Reviewer
Danielle Walker, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Rebecca Franklin discloses: Independent contractor relationships with Fishawack Communications (relationship terminated).
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring activity (Modules 1, 2 and 3) for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advanced Practice Providers
Physician Assistants may claim a maximum of 1.5 Category 1 credits for completing Modules 1, 2 and 3. NCCPA accepts AMA PRA Category 1 CreditTMÂ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMÂ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.5 contact hours may be earned by learners who successfully complete these continuing nursing education modules. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE module.
Modules 1, 2 and 3 are awarded 1.5 ANCC pharmacotherapeutic contact hours.
Date of original release (Module 3): 28 November 2024. Date credits expire: 28 November 2025.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
EBAC® Accreditation
touchIME is an EBAC® accredited provider since 2023.
This module is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1.5 hours of effective education time.
The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.
Requirements for Successful Completion
Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.
Time to complete Modules 1, 2 and 3: 1.5 hours
If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org
-
PART 9 of 9 Skip to Modules
- Time: 14:17
Module 3 - Part 3: Optimizing outcomes in late-stage NSCLC: Key learnings
Dr Helena Yu, course director and thoracic oncologist, provides an overview of the three modules focusing on EGFR-mutant and wildtype non-small cell lung cancer (NSCLC). In this session, she summarizes the key learnings from each module while also providing timely updates on data presented at the World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) 2024 congresses. Dr Yu highlights how these recent findings can impact current NSCLC practices, addresses outstanding practice gaps, and outlines future directions in the rapidly evolving field of lung cancer management.
After watching this activity, participants should be better able to:
- Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing
- Describe the evolving landscape for biomarker testing in NSCLC and how this may impact current and future treatment decision making
- Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, including lung cancer specialists, pulmonologists, pathologists and oncology nurses involved in the management of patients with NSCLC.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
Ms Jackie Fenemore discloses: Advisory board/panel fees from Roche (relationship terminated).
Prof. Egbert Smit discloses: Advisory board or panel fees from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen Pharmaceuticals, Merck Serono, MSD, Pfizer and Takeda. Consultancy fees from Eli Lilly. Grants/research support from AstraZeneca, BMS and Merck.
Content Reviewer
Danielle Walker, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Rebecca Franklin discloses: Independent contractor relationships with Fishawack Communications (relationship terminated).
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring activity (Modules 1, 2 and 3) for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advanced Practice Providers
Physician Assistants may claim a maximum of 1.5 Category 1 credits for completing Modules 1, 2 and 3. NCCPA accepts AMA PRA Category 1 CreditTMÂ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMÂ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.5 contact hours may be earned by learners who successfully complete these continuing nursing education modules. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE module.
Modules 1, 2 and 3 are awarded 1.5 ANCC pharmacotherapeutic contact hours.
Date of original release (Module 3): 28 November 2024. Date credits expire: 28 November 2025.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
EBAC® Accreditation
touchIME is an EBAC® accredited provider since 2023.
This module is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1.5 hours of effective education time.
The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.
Requirements for Successful Completion
Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.
Time to complete Modules 1, 2 and 3: 1.5 hours
If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org
Content to enrich this programme...
touchIN CONVERSATION
Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies
This activity is CE/CME accredited
touchTALKS
Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs
This activity is CE/CME accredited
touchFOCUS
Targets in early NSCLC: A focus on EGFR-mutant treatment options
This activity is CE/CME accredited
touchFOCUS
Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches
This activity is CE/CME accredited
touchPANEL DISCUSSION
Expanding HER2 horizons: Implications for NSCLC and beyond
This activity is CE/CME accreditedTopics covered in this activity
Haematology / Rare Diseases
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 1000+ topical and insightful peer-reviewed journal articles
- 10 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGY
Sign me up!Got 2 minutes?
Your feedback is important to us
1 = strongly disagree; 5 = strongly agree* = Mandatory Field
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register now for FREE Access
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Sign up with an Email
Or use a Social Account.
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
